Greenwich LifeSciences (GLSI) Operating Expenses (2019 - 2026)

Greenwich LifeSciences (GLSI) has 7 years of Operating Expenses data on file, last reported at $9.2 million in Q4 2025.

• Quarterly Operating Expenses fell 5.5% year-over-year to $9.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $19.4 million (up 10.27% YoY) and the FY2025 annual result came in at $19.4 million, up 10.27% from the prior year.
• Operating Expenses grew to $9.2 million in Q4 2025, from $3.7 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $9.7 million in Q4 2024 to a low of $600606.0 in Q1 2021.
• A 5-year average of $3.0 million and a median of $2.5 million in 2023 frame the typical range for Operating Expenses.
• Annual changes were most pronounced in 2021 — Operating Expenses jumped 258.05% — and 2025, when it fell 5.5%.
• Tracing GLSI's Operating Expenses over 5 years: stood at $2.4 million in 2021, then climbed by 21.77% to $2.9 million in 2022, then decreased by 2.03% to $2.8 million in 2023, then soared by 242.36% to $9.7 million in 2024, then retreated by 5.5% to $9.2 million in 2025.
• The last three Operating Expenses figures came in at $9.2 million (Q4 2025), $3.7 million (Q3 2025), and $3.8 million (Q2 2025), per Business Quant data.